Yesterday, Superdrug released its annual financial results on Monday. It showcased a substantial double-digit revenue increase and remarkable profit growth driven by strong retail store sales and volume growth in 2023. The UK-based health and beauty retail giant reported an 11.8% rise in sales, reaching £1.528 billion, and its market share expanded for the third consecutive year, hitting 10.6%, up from 8.9% in 2020. Volume sales also rose by 4.2%.
The company’s pre-tax earnings saw a significant boost, increasing by 43% to £111.6 million. Although Superdrug did not disclose a net profit figure, operating profit rose from £88.4 million to £121.9 million, and the operating margin improved to 8% from 6.5% the previous year.
Superdrug’s performance was attributed to strong retail store performance, increased sales volume, and continued own brand growth. The company continued its investment in new and upgraded stores, opening 14 new locations in key retail destinations such as The Trafford Centre in Manchester, Brent Cross Shopping Centre, and Braehead, its largest store in Scotland.
These larger stores feature more spacious layouts and a wider product range, including Beauty Studios, premium fragrance counters, and health services. Additionally, Superdrug modernized 45 existing stores over the year, enhancing them with new shop fronts, upgraded Wi-Fi, new floor layouts, improved signage, and energy-efficient LED lighting.
Own brand products played a crucial role in driving volume sales growth. For instance, the Optimum Collagen Night Cream saw high demand, selling out twice in the first half of the year due to positive reviews. The Studio London cosmetic range also continued to expand. Moreover, exclusive product launches, such as Biore SPF, Nyx X Barbie, and fragrances by Billie Eilish, significantly contributed to sales.
The Health & Beautycard customer loyalty program remains vital, with over 60% of total sales made through members, highlighting increasing brand loyalty and competitive pricing.
